Abstracts tagged "outcomes"

Abstract Number: 333 • 2019 ACR/ARP Annual Meeting
Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients
Justin Li¹, David Yin ¹, Zheng Wang ¹, Mark Brigham ¹, Brian LaMoreaux ², Jeffrey Kent ², Megan Francis-Sedlak ², Richard Johnson ³, Nandini Hadker ¹ and Gavin Miyasato ¹, ¹Trinity Partners, Waltham, MA, ²Horizon Therapeutics plc, Lake Forest, IL, ³University of Colorado Denver, Aurora, CO
Background/Purpose: Although gout has been shown to be associated with poor renal outcomes among chronic kidney disease populations, this relationship is not well understood among…
Abstract Number: 869 • 2019 ACR/ARP Annual Meeting
Clinical Manifestations of Patients with Eosinophilic Granulomatosis with Polyangiitis in a Large North American Cohort
Irena Doubelt¹, David Cuthbertson ², Simon Carette ¹, Nader A. Khalidi ³, Curry L. Koening ⁴, Carol Langford ⁵, Carol A. McAlear ⁶, Larry W. Moreland ⁷, Paul Monach ⁸, Philip Seo ⁹, Ulrich Specks ¹⁰, Antoine Sreih ¹¹, Steven Ytterberg ¹⁰, Peter A. Merkel ¹², Christian Pagnoux ¹ and VCRC Vasculitis Clinical Research Consortium ¹³, ¹Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ²University of South Florida, Tampa, FL, ³McMaster University, Hamilton, ON, Canada, ⁴University of Utah Hospital, Salt Lake City, UT, ⁵Cleveland Clinic, Cleveland, OH, ⁶University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Johns Hopkins Medicine, Baltimore, MD, ¹⁰Mayo Clinic College of Medicine, Rochester, MN, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Univeristy of Pennsylvania, Philadelphia, PA, ¹³University of Pennsylvania, Division of Rheumatology, philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, systemic necrotizing small-vessel vasculitis, with only a few published North American series. This project aimed to…
Abstract Number: 604 • 2018 ACR/ARHP Annual Meeting
Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
Gyanendra Pokharel¹, Rob Deardon¹, Cheryl Barnabe², Vivian P. Bykerk³, Susan J. Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Carol Hitchon⁷, Edward C. Keystone⁸, Janet E. Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹ and Glen Hazlewood¹², ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁶Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada, ¹²Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Remission is the goal of rheumatoid arthritis (RA) treatment, but ACR responses are more commonly measured in clinical trials. As such, data on remission…
Abstract Number: 2406 • 2018 ACR/ARHP Annual Meeting
Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt–Koyanagi–Harada Disease (VKH) in Children and Adolescents
Andreas Reiff, Children’s Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Chronic uveitis is a common manifestation of pediatric rheumatologic conditions and may result in irreversible blindness and long term disability. While chronic anterior uveitis…
Abstract Number: 717 • 2018 ACR/ARHP Annual Meeting
The Burden of Chronic Kidney Disease in Systemic Lupus Erythematosus (SLE): A Nationwide Epidemiologic Study
Arthur Mageau¹, Jean Francois Timsit¹, Anne Perozziello¹, Stephane Ruckly¹, Claire Dupuis¹, Lila Bouadma¹, Thomas Papo¹ and Karim Sacre², ¹Université Paris-Diderot, Paris, France, ²Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: Lupus nephritis occurs in about 50% of SLE patients. We aimed to analyze the impact of chronic kidney disease (CKD) on major clinical outcomes…
Abstract Number: 2427 • 2018 ACR/ARHP Annual Meeting
Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series
Marianna Meroni¹, Maria De Santis², Elena Generali², Angela Ceribelli³, Marta Caprioli³, Giacomo Maria Guidelli², Natasa Isailovic², Gaetano Maria Fara⁴, Carlo Selmi² and Maurizio Cutolo⁵, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁴Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy
Background/Purpose: Certolizumab pegol (CTZ) is a TNFα inhibitor indicated for the treatment of women affected by rheumatoid arthritis (RA) throughout the whole pregnancy. Some concern,…
Abstract Number: 763 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis
Kubra Bugdayli¹, Cynthia S. Crowson², Ladan Zand³, Mariam P. Alexander⁴, Lynn D. Cornell⁴ and Vaidehi R. Chowdhary⁵, ¹Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ⁴Anatomic Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Comparison of clinical characteristics and outcome between isolated and classic lupus nephritisBackground/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely,…
Abstract Number: 2438 • 2018 ACR/ARHP Annual Meeting
Risk and Severity of Adverse Pregnancy Outcomes in Women with Systemic Sclerosis in Taiwan
Chen I Hsieh¹, Shue Fen Luo² and Chang-Fu Kuo³, ¹Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Chang Gung University, Taoyuan County, Taiwan, ³Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Patients with different autoimmune rheumatic diseases are subject to different pregnancy outcomes because of deviant immunity. Systemic sclerosis is known to be associated with…
Abstract Number: 834 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of IgA Vasculitis in Children and Adults: A Retrospective Cohort Study
Michel Villatoro-Villar¹, Cynthia S. Crowson^1,2, Kenneth J. Warrington³, Ashima Makol¹, Steven R. Ytterberg³ and Matthew J. Koster¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Differences in both presentation and outcome based on age of diagnosis have been described in patients with IgA vasculitis (IgAV) but data are limited…
Abstract Number: 2512 • 2018 ACR/ARHP Annual Meeting
Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar
Lisa Baganz¹, Yvette Meißner¹, Perter Herzer², Jürgen Braun³, Anett Gräßler⁴, Anja Strangfeld⁵ and Angela Zink⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Scientific Advisory Board, Munich, Germany, ³Ruhr-University Bochum, Bochum, Germany, ⁴Rheumatologist, Pirna, Germany, ⁵Epidemiology, German Rheumatism Research Center, Berlin, Germany, ⁶Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: The number of biosimilars approved for the treatment of rheumatoid arthritis (RA) is constantly increasing. Until now, there are just a few analyses investigating…
Abstract Number: 941 • 2018 ACR/ARHP Annual Meeting
Causal Inference Methods for the Effect of Rheumatoid Arthritis on Mortality Independent of Lifestyle and Clinical Factors before and after RA Diagnosis
Jeffrey A. Sparks¹, Kazuki Yoshida^1,2, Tzu-Chieh Lin³, Carlos Camargo⁴, Benjamin Raby⁵, Hyon K. Choi⁶, Medha Barbhaiya⁷, Sara K. Tedeschi¹, Bing Lu⁸, Karen Costenbader¹ and Elizabeth Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Amgen, Thousand Oaks, CA, ⁴Emergency Medicine, Massachusetts General Hospital, Boston, MA, ⁵Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: RA is associated with increased total, cardiovascular, and respiratory mortality compared to the general population. This excess RA mortality may be mediated through lifestyle,…
Abstract Number: 2594 • 2018 ACR/ARHP Annual Meeting
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Kurt de Vlam¹, Alexis Ogdie², Andrew G Bushmakin³, Joseph C Cappelleri³, Roy Fleischmann⁴, Peter C. Taylor⁵, Valderilio F Azevedo⁶, Lara Fallon⁷, Anna Maniccia⁸, John Woolcott⁹ and Philip J. Mease¹⁰, ¹UZ Leuven, Leuven, Belgium, ²University of Pennsylvania, Philadelphia, PA, ³Pfizer Inc, Groton, CT, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵University of Oxford, Oxford, United Kingdom, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Pfizer Canada, Montreal, QC, Canada, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Collegeville, PA, ¹⁰Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…
Abstract Number: 1191 • 2018 ACR/ARHP Annual Meeting
The Importance of Quantitative Assessment of Joint/Organ Damage and Patient Distress in Addition to Inflammatory Activity in Routine Clinical Care
Theodore Pincus, Isabel Castrejón and Joel A. Block, Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Quantitative measures such as laboratory tests and pooled indices have advanced clinical rheumatology care far beyond narrative decisions. These measures generally are directed to…
Abstract Number: 2605 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson², Michael J. Nissen³, Eirik K Kristianslund⁴, Maria José Santos⁵, Kari Eklund⁶, Ziga Rotar⁷, Björn Gudbjornsson⁸, Fatos Onen⁹, Catalin Codreanu¹⁰, Ulf Lindström¹¹, Cem Gabay³, Tore Kvien⁴, Anabela Barcelos⁵, Kalle Aaltonen⁶, Matija Tomšič⁷, Thorvardur Love⁸, Gerçek Can⁹, Ruxandra Ionescu¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Karel Pavelka¹², Marleen van de Sande¹³, Irene van der Horst-Bruinsma¹⁴, Juan J. Gomez-Reino¹⁵, Carlos Sánchez-Piedra¹⁶, Gary J Macfarlane¹⁷, Florenzo Iannone¹⁸, Lise Hyldstrup¹, Niels Steen Krogh¹⁹, Mikkel Østergaard¹ and Merete Lund Hetland¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Gothenburg, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ⁸ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ⁹TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ¹⁰RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ¹¹ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Amsterdam, Netherlands, ¹⁴ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁵BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁶BIOBASADER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁷BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁸GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁹ZiteLab ApS, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research…
Abstract Number: 1259 • 2018 ACR/ARHP Annual Meeting
Driving Performance and Safety in Rheumatoid Arthritis: A Systematic Review
Daniel Zhou¹, Ted R. Mikuls², Cynthia Schmidt³, Bryant R. England⁴, Debra A Bergman⁵, Matthew Rizzo⁶, Jennifer Merickel⁶ and Kaleb Michaud^7,8, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ³McGoogan Library of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, ⁷Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Automobile driving represents an instrumental activity of daily living (IADL). Symptoms accompanying RA, including fatigue, joint pain and stiffness, decreased strength, reduced mobility, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].